Background and purpose: Alterations in the gut microbial community composition may be influential in neurological disease. Microbial community profiles were compared between early onset pediatric multiple sclerosis (MS) and control children similar for age and sex. Methods: Children ≤18 years old within 2 years of MS onset or controls without autoimmune disorders attending a University of California, San Francisco, USA, pediatric clinic were examined for fecal bacterial community composition and predicted function by 16S ribosomal RNA sequencing and phylogenetic reconstruction of unobserved states (PICRUSt) analysis. Associations between subject characteristics and the microbiota, including beta diversity and taxa abundance, were identified using non-parametric tests, permutational multivariate analysis of variance and negative binomial regression. Results: Eighteen relapsingÀremitting MS cases and 17 controls (mean age 13 years; range 4-18) were studied. Cases had a short disease duration (mean 11 months; range 2-24) and half were immunomodulatory drug (IMD) na€ ıve. Whilst overall gut bacterial beta diversity was not significantly related to MS status, IMD exposure was (Canberra, P < 0.02). However, relative to controls, MS cases had a significant enrichment in relative abundance for members of the Desulfovibrionaceae (Bilophila, Desulfovibrio and Christensenellaceae) and depletion in Lachnospiraceae and Ruminococcaceae (all P and q < 0.000005). Microbial genes predicted as enriched in MS versus controls included those involved in glutathione metabolism (MannÀWhitney, P = 0.017), findings that were consistent regardless of IMD exposure. Conclusions: In recent onset pediatric MS, perturbations in the gut microbiome composition were observed, in parallel with predicted enrichment of metabolic pathways associated with neurodegeneration. Findings were suggestive of a pro-inflammatory milieu.
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Introduction
Alterations in the gut microbiota may be influential in disease, including neurological and autoimmune conditions [1, 2] . Humans comprise 10 times more microbial than human cells, of which >90% reside in the gastrointestinal tract [3, 4] . The role of these microbial communities (the gut microbiota) includes synthesis of vitamins, modulation of the immune system and resistance to infection [5] . Multiple sclerosis (MS) is considered an autoimmune disease, with both genetic and early life environmental exposures (including infections) implicated as risk factors. Recent studies suggest a role for the gut microbiota in MS, with most evidence derived from experimental animal models. Emerging work reported perturbation in the adult MS gut microbiota relative to healthy controls [6, 7] . Whilst of major interest, adults with MS have had a lifetime of exposures, with potential for disease trigger(s) or modifiers to have occurred years previously or accumulated over decades. Pediatric MS, whilst relatively rare, represents a unique opportunity to examine disease processes after few years of life have accrued, narrowing the search for potential disease triggers. A pilot study was conducted to explore the gut microbiota in early onset pediatric MS, compared to controls of similar age and sex. The potential influence of other characteristics such as immunomodulatory drug (IMD) exposure was also explored to guide future studies.
Methods
Children ≤18 years old attending a University of California, San Francisco (UCSF), pediatric clinic (e.g. a general or MS-specific clinic) were invited to participate in an environmental risk factor study; those providing a stool sample formed the current study cohort. MS cases were within 2 years of symptom onset. Use of IMDs or systemic corticosteroids was permissible, although prior cytotoxic immunosuppressant exposure was not. In the absence of consensus on the most appropriate controls for microbiota studies, controls of similar age and sex were selected, free from autoimmune disorders (conditions such as asthma and eczema were allowed), with neither parent diagnosed with MS nor a related disorder. Neither cases nor controls were exposed to systemic antibiotics in the 2 months before stool collection.
Demographic, lifestyle and clinical characteristics
The children's characteristics were obtained from the physician and research coordinator (JH) clinic visits (using standardized forms and chart abstraction), as well as questionnaires which could be completed at home (summarized in Table S1 ). For the current study, the following characteristics were included: sex, age, race (white, non-white), ethnicity (Hispanic, nonHispanic), comorbidity (present, absent), body mass index [healthy or underweight, overweight or obese (<85th, ≥85th percentile)], fatÀfiber diet groups [high fat/low fiber, based on recent diet [8] (yes, no)], early life diet (breastfed <12, ≥12 months), antibiotics in the first year of life (yes, no), attendance at day-care (yes, no), mode of delivery (vaginal, caesarean section), prior close contact with animals [direct physical contact (ever, never); dog or cat slept in the house on a regular basis (yes, no)]. MS-specific clinical characteristics included age at MS symptom onset; disability (Expanded Disability Status Scale score, EDSS); relapses pre-stool sample (including number, severity and location); use of IMDs and systemic corticosteroids (in the previous 2 months).
Stool sample collection, DNA extraction and 16S rRNA profiling
The parent was asked to collect the child's first stool of the day and to ship on ice (via FedExÒ) to UCSF where it was stored at À80°C before processing. DNA was extracted from approximately 25 mg of stool using the PowerSoilÒ DNA Isolation Kit (MO BIO Laboratories Inc., Carlsbad, CA, USA) according to the manufacturer's recommendations. The V4 hypervariable region of the bacterial 16S rRNA gene was amplified in triplicate as previously described [9] and then combined, purified and pooled in equimolar concentrations. Sequencing was performed via the Illumina MiSeq platform using a 251 9 151 basepair run. The 16S rRNA reads were clustered at ≥97% similarity into operational taxonomic units (OTUs), and the resulting OTU table was singly rarefied to 201 546 reads per sample. OTUs were assigned taxonomy using the Greengenes database and analysis was performed using QIIME (Quantitative Insights into Microbial Ecology) [10, 11] .
Alpha and beta diversity
Alpha diversity was expressed as evenness, richness and Faith's phylogenic diversity metric, using the vegan and picante packages [R] . Beta diversity was calculated using a Canberra distance matrix, a nonphylogenetic, equal-weight measure where each OTU affects the distance value equally.
Predicted metagenome
Metagenomic predictions were made using PICRUSt [12] (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) and summarized as KEGG (Kyoto Encyclopaedia of Genes and Genomes) pathways.
Statistical analyses
Epidemiological characteristics were presented descriptively. The gut microbiota metrics were primarily compared between cases and controls and secondly by IMD exposure. Additional exploratory comparisons were performed for the diversity metrics only, including characteristics selected a priori either as potential confounders or if a reasonable difference (e.g. ≥10% difference in proportions) between cases and controls existed (sex, age, race, ethnicity, fat/fiber groups, breastfeeding, IMD exposure and, for the MS cases only, EDSS, corticosteroid use or history of a recent relapse) [13] . Alpha diversity was compared between groups using non-parametric tests (MannÀWhitney or KruskalÀWallis); beta diversity was explored using principal coordinate analyses (PCoA) and permutational multivariate analysis of variance (PERMA-NOVA). At the taxon level, the relative abundances of individual OTUs for the primary (cases and controls) and secondary (IMD na€ ıve versus IMD exposed cases versus controls) comparisons were explored using generalized linear models (negative binomial regression), with findings expressed as rate ratios (RR) and 95% confidence intervals (95% CI), along with P and q values (false discovery rate adjusted P values; <0.05 was considered significant). All other comparisons were made without adjustment. Phylum-level and KEGG pathway abundance were explored using non-parametric tests. Statistical analyses were performed using R (Version 3.0.2) [14] and the Statistical Package for the Social Sciences (SPSS for Windows, Version 22.0. Armonk, NY, USA: IBM Corp., 2013).
Secondary platform -DNA microarray
In the absence of a validation cohort, an additional secondary platform was used to corroborate the 16S rRNA sequencing data, using the G3 PhyloChipTM (Second Genome Inc., San Francisco, CA, USA), Appendix S1.
The University of California San Francisco Institutional Review Board approved the study.
Results
Between November 2011 and November 2013, 18 MS patients (10 girls, eight boys) and 17 controls (nine girls, seven boys) fulfilled the study criteria. The mean age at stool collection was 13.0 years (SD 3.82; range 4-18). Although controls averaged 1 year older than cases and more self-identified as white (77% controls, 50% cases), the proportion of Hispanics was relatively similar (44% cases, 35% controls) and no characteristic (Table 1 ) differed significantly between cases and controls (all P > 0.1, not shown).
For cases, the mean disease duration at stool collection (from MS symptom onset) was 10.6 months (SD 6.34; range 2-23), the median EDSS at enrolment was 2.0 (range 0-4.0), half were exposed to an IMD for MS (five glatiramer acetate, three beta-interferon, one natalizumab) and six (33%) to a systemic corticosteroid (in the 2 months pre-stool sample). All met McDonald criteria and had relapsingÀremitting MS (Table 2); see Tables S2, S3 for additional characteristics.
Gut microbiota profiling
All samples underwent 16S rRNA sequencing, although one control sample produced insufficient read depth and was excluded from these analyses. The majority of samples produced a 16S rRNA PhyloChip profile (three control samples produced insufficient 16S rRNA amplicon for analyses by this secondary profiling technique).
Alpha and beta diversity
Gut microbiota alpha diversity did not differ significantly between cases and controls (all P > 0.2 for the diversity metrics, Table S4 ). Whilst there was a trend for greater alpha diversity in the IMD exposed cases > controls > IMD na€ ıve cases, no comparison reached significance (all P > 0.05, Fig. 1a and Table S4 ). However, IMD exposure was identified as a significant factor that explained 6.8% of the variation in gut microbiota beta diversity (Canberra distance matrix; IMD exposed versus na€ ıve cases versus controls, P = 0.012, PERMANOVA). When only MS cases were considered in this analysis, IMD exposure explained a slightly larger proportion (7.1%) of the observed compositional variation (P = 0.016, Fig. 1b and Table S4B ), indicating that IMD exposure was associated with differences in gut microbiota composition. This was supported by an (ad hoc) comparison of compositional distance from controls -IMD exposed cases exhibited gut microbiota that were more similar to those of control subjects than those of IMD na€ ıve patients (Fig. 1c , Bonferroni-corrected two-sample t test, P < 0.001). Hispanics exhibited lower community evenness compared to non-Hispanics (P = 0.040); however, no other measured variables reached significance (all P > 0.1, data not shown).
Taxonomic characteristics of cases and controls
From the 16S rRNA sequencing data, a total of 25 134 OTUs were identified. These were primarily bacterial (>99%) with the remainder belonging to the Archaea. In total, 14 phyla, 24 classes, 37 orders and 61 families were identified. Twelve phyla were common to cases and controls, and two were found exclusively in cases (Synergistetes and Lentisphaerae). As previously described in other US populations [15] , Bacteroidetes and Firmicutes dominated the gut microbiome of study participants (Fig. 2a) . Cases had 2.5 times the abundance of Actinobacteria compared to Comorbid conditions were collected pre-stool sample (but were not necessarily present pre-MS onset). For cases: headache (n = 1); atopic dermatitis/eczema (n = 1); long-term constipation (n = 1); history of shingles (n = 1); history of seizures (n = 1); reactive airways disease and headache (n = 1); scoliosis (n = 1). For controls: kyphosis (n = 1); Raynaud phenomenon (n = 1); asthma (n = 2); pancreatitis (n = 1).
b Body mass index (BMI), height (kg)/weight (m 2 ), with age-and sex-specific percentiles (Table S1 ). One individual (case) was below the 5th percentile; 3/18 cases and 3/17 controls were ≥95th percentile (obese).
c Recent diet derived from the Block Kids Food Screener (NutritionQuest©), recorded over 1 week (Table S1 for further details).
controls (95% CI 1.3-4.9, P = 0.008) (Fig. 2b) . Whilst no other phylum reached significance (cases versus controls), IMD status influenced findings; the rate ratio for Actinobacteria was attenuated for the IMD na€ ıve cases (decreasing to 1.3; 95% CI 0.58-2.9, P = 0.527 versus controls) but remained significantly elevated in the IMD exposed cases (RR = 3.7; 95% CI 1.6-8.3, P = 0.002) (Fig. 2b) . IMD based differences in two other phyla (Tenericutes and Cyanobacteria) were also observed ( Fig. 2b) , suggesting that even at the phylum level IMD exposure significantly influences microbiota composition.
At the individual OTU level, 160 of the 25 134 taxa (0.6%) were significantly enriched and 163 taxa (0.6%) depleted in MS cases compared to controls (all P, q < 0.05, negative binomial regression, Table S5) . At the order level, 57% (91/160) of the enriched and 49% (79/163) of depleted taxa belonged to Clostridiales (Firmicutes), with the second most common being Bacteroidales (Bacteriodetes), representing 26% (41/ 160) and 45% (74/163), respectively. Although these dominated, a range of additional taxa were found to be significantly altered in relative abundance across these groups (Table S5 ). Some of the most significant (i.e. lowest P and q values) are depicted in Fig. 3a, b and summarized in the context of the wider microbiota literature in Table S6 . For example, MS cases exhibited 3.0 times the relative abundance of Bilophilia (order Desulfovibrionales) compared to controls (95% CI 2.9-3.2). Members of the Bifidobacterium, Desulfovibrio and Christensenellaceae family were similarly enriched (RR > 4), amongst others (Fig. 3a) . There was additionally evidence for decreased relative abundances of members of the Clostridiales order (e.g. the butyrate producing Lachnospiraceae and Ruminococcaceae). A comparison of the absolute differences in genera abundance for cases and controls included enrichment for Akkermansia, Parabacteroides, Methanobrevibacter (Archaea) and Bacteroides and depletion for members of the orders Bacteroidales and Clostridiales (genus unknown) (Table S5 for all findings). The direction of findings and those in Fig. 3a, b were similar, regardless of IMD exposure (aside from one taxon belonging to the Ruminococcaceae family) (Fig. 3a) . The influence of IMD exposure status on the primary comparisons (cases versus controls) are depicted in Table S5 , with the original rate ratios for these secondary comparisons in Table S7 . Briefly, 45 of the 160 taxa enriched in MS relative to controls were depleted in IMD na€ ıve cases and 40/160 were depleted in IMD exposed cases (all relative to controls; most being from the Clostridiales order, n = 28 and 25, respectively). Fewer (seven) of the 163 depleted taxa were similarly affected (Table S5B) .
Validation of findings
The G3 phylogenetic microarray data broadly concurred with the main findings in that cases and controls did not significantly differ in alpha diversity indices (all P > 0.1, data not shown). Additional results, including comparisons with findings from the primary platform, are provided in Table 3, Table S6 and Appendix S1.
Predicted metagenome
From the 16S rRNA sequencing data, 271 KEGG pathways were identified; 27 were predicted as Relapse rate = relapse count/disease duration. Note, however, those cases with the shortest disease durations pre-stool sample can influence the apparent relapse rates as follows: a very short disease duration implies less opportunity for a relapse to occur, and therefore often the relapse rate was zero; however, if a relapse did occur, the resulting relapse rate can appear high (inflated) because of the small denominator (disease duration). c 'IMD na€ ıve' indicates never exposed pre-stool sample. 'IMD exposed' indicates ever exposed pre-stool sample. All were also currently exposed (at the time of stool collection) as follows: beta-interferon (n = 3); glatiramer acetate (n = 5); natalizumab (n = 1). No child had switched or stopped an IMD (although one child had previously been exposed to plasma exchange before taking glatiramer acetate). (Table S8) . Compared to controls, pathways predicted as enriched in the microbiome of MS patients included those involved in glutathione metabolism (P = 0.017) and lipopolysaccharide biosynthesis (IMD na€ ıve cases only, P = 0.008) (Fig. S1A) . IMD exposure was associated with enrichment of several Table S4A . (b) The immunomodulatory drug [IMD] exposure status of the children with MS was associated with gross perturbations in the overall microbial community composition: a principal coordinate analyses (PCoA) plot indicating the similarity and difference's in the gut microbiota composition of the IMD exposed and IMD naı¨ve MS cases. Each dot represents one child with MS, as shown. IMD exposed children (n = 9); IMD naive children (n = 9); all exposed cases were currently on IMD treatment at the time of the stool sample; the na€ ıve cases had never been exposed to an IMD. The controls are not depicted. PC1 and PC2 represent the top two principal coordinates that captured most diversity (generated using the Canberra dissimilarity matrices); the percentages represent the fraction of the diversity captured by each coordinate shown. Ellipses, 95% confidence intervals (via SE of weighted mean axes values). IMD exposure was associated with differences in beta diversity, explaining 7.1% of the gut microbiota variation (Canberra metric, IMD exposed versus na€ ıve cases, P = 0.016, Adonis). (c) IMD exposed subjects are compositionally more similar to the controls (less distant, as measured by Canberra) than the IMD na€ ıve cases (Bonferronicorrected two-sample t test, P < 0.001). The box plot depicts the Canberra compositional distance of cases (IMD exposed and na€ ıve) from controls.
pathways, including those related to immune responses and folate biosynthesis (Fig. S1B ).
Discussion
Perturbations in the gut microbiota of children very early in their MS disease course were observed relative to children without MS. These perturbations were not evident at the beta diversity level, but rather were characterized by discrete taxonomic enrichments and depletions.
This suggests that recent MS onset may be associated with more subtle changes in a limited number of microbial taxa, rather than large shifts in the community composition.
In contrast, IMD exposure was associated with a substantial portion of microbiota compositional variation. Microbial taxa alterations associated with MS which remained significant irrespective of IMD exposure included an increase in relative abundance of members of the Desulfovibrio, Bifidobacterium genera and members of the recently identified and highly 50%   60%   70%   80%   90%   100%   HC5  HC7  HC15  HC11  HC6  HC16  HC13  HC4  HC12  HC14  HC1  HC2  HC8  HC10  HC17  HC3  MS9  MS16  MS2  MS3  MS10  MS4  MS13  MS7  MS15  MS6  MS12  MS14  MS1  MS5  MS18  MS8  MS17 Phylum-level differences were observed for MS cases (n = 18) versus controls (n = 16) but were influenced by the immunomodulatory drug exposure status of the cases. Controls formed the reference group. Rate ratios derived from the negative binomial regression; CI, confidence interval. IMD, immunomodulatory drug [n = 9 MS cases were na€ ıve, nine were exposed (five glatiramer acetate, three beta-interferon, one natalizumab)]. Only phyla shown where a significant difference was observed (P < 0.05) in at least one comparison. No adjustments made for multiple comparisons.
heritable Christensenellaceae family [16] . There was additionally evidence for decreased relative abundances of members of the Clostridiales order (e.g. the butyrate producing Lachnospiraceae and Ruminococcaceae). Combined, these data indicate that early dysregulation in MS involves an increase in proinflammatory and a decrease in anti-inflammatory gut microbiota milieu [17, 18] . The suggestion of a heritable taxon contributing to MS in a disease with known (host) familial and genetic contribution deserves further investigation [19] . No studies were found exploring the potential association between the gut microbiota and pediatric MS or with individuals sampled close to MS onset. Remarkably, however, patterns are emerging from the sparse literature, despite different platforms and approaches (summarized in Table 3 ). One USA-based pilot study compared seven relapsingÀremitting MS Table S5 ; all P and q values <0.000005. All findings are shown in Table S5 including full taxonomic nomenclature; the lowest available shown here (typically family or genus). In total, of the 25 134 taxa identified, 160 were significantly enriched in MS cases; 163 were depleted, relative to controls. The most (statistically) significant findings are depicted here for illustrative purposes, representing OTU# (Fig. 3a, 4 473 664). Example interpretation of results: Children with MS had 3.0 times the abundance of Bilophila (95% CI 2.9-3.2) than control children. All depicted findings were consistent, regardless of IMD exposure, except for *Ruminococcaceae which, whilst significantly enriched for all cases versus controls (a) and for IMD exposed children (RR = 10.9; 95% CI 9.4-12.3) relative to controls, was significantly depleted for the IMD na€ ıve children (RR = 0.76; 95% CI 0.61-0.95). See Table S6 for a summary of the taxa depicted in (a), (b) in relation to the secondary platform (DNA microarray) wider gut microbiota literature. The rate ratios and 95% confidence intervals are derived from negative binomial regression models which may not meet the default convergence limits. Tables S5, S7 Baranzini et al.,
(New
York and San Francisco, California, USA) [24] Not specified (in the published abstract) Table S5A CI, confidence interval; EAE, experimental autoimmune encephalomyelitis; GA, glatiramer acetate; IFNB, beta-interferon; IMD, immunomodulatory drug; OTU, operational taxonomic unit; RR, rate ratio (from negative binomial regression); RRMS, relapsingÀremitting multiple sclerosis; no. cases/no. controls, number cases/number controls with fluorescence on chip (>0). No formal statistical comparisons were performed for presence versus absence of taxa. Total possible cases 18; controls 14. a 9/20 (45%) were exposed to beta-interferon (derived from Table S1 ) [7] . No formal comparisons for IMD exposed/unexposed individuals reported. No P value given; authors stated 'the Shannon index, a metric for evaluating bacterial diversity, was not significantly different between the samples obtained from HC40 (3.39 AE 0.29) and MS20 subjects (3.29 AE 0.46)' [7] .
b P values derived from non-parametric tests ( Fig. 1 and Table S4A ). All P > 0.05 for all comparisons with diversity measured as richness, evenness or Faith's: all cases versus controls; IMD na€ ıve cases versus IMD exposed cases versus controls; IMD na€ ıve cases versus IMD exposed cases; IMD na€ ıve cases versus controls (P > 0.05, MannÀWhitney or KruskalÀWallis). were Bacteroides (genus), all P and q < 0.05, Table S5B .
f P values derived from the Adonis test, using the Unifrac metric to assess beta diversity. Additional (post-baseline) IMD exposed cases were included for this comparison, increasing numbers to five IMD exposed (all were glatiramer acetate) versus two IMD na€ ıve MS cases. [6] g P values derived from the Adonis test, using the Canberra metric to assess beta diversity, All study results reported here were based on cross-sectional findings. Whilst two studies [6, 7] included a longitudinal, i.e. repeated sampling, component (e.g. Cantarel et al.
[6] included a vitamin D supplementation intervention), the cross-sectional or baseline comparisons (pre-intervention) are reported here to allow comparisons with the current study.
n Possible confounder was constipation; whilst gut transit time was not measured, comorbidity information was collected; one child (a case) was reported as having 'long-term constipation'. This child also had high abundances of Methanobrevibacter.
and eight healthy control women (all were non-Hispanic whites) [6] . A second study from Japan [7] included 20 relapsingÀremitting MS adults and 40 controls. Similar to our findings, no overall differences were found in the gut microbiota composition between cases and controls (beta diversity in the former study [6] and alpha diversity in the latter). Both studies identified discrete taxon-level differences as characteristic of cases [6, 7] . In addition, IMD exposure was also related to microbiota compositional variation [6] , concurring with our findings. Whilst 9/ 20 individuals in the Japanese study were IMD exposed, no formal comparisons by IMD status were reported [7] . Common to both USA-based studies was the significant depletion of Faecalibacterium and Bacteroidaceae members in MS cases (independent of IMD treatment). Faecalibacterium prausnitzii (the species identified as depleted in MS cases in our study) has been shown to exert anti-inflammatory effects and its presence is considered a 'sensor and marker of health' [20, 21] . Its depletion has also been observed in children newly diagnosed with the autoimmune condition Crohn's disease [20, 22, 23] .
Additional gut microbiota studies in MS have appeared as conference proceedings only [24, 25] or primarily in animal models of MS [2, 26] . Briefly, significant enrichment of the pro-inflammatory Enterobacteriaceae family have been reported in MS relative to controls (in women only) [25] , a finding observed also in this study regardless of sex. Depletion of the Butyricimonas genus and enrichment for the Archaea Methanobrevibacter in 53 adults with MS compared to 44 controls also concurred with our observations [24] . Although consistent with the broader literature, this Archaea was not ubiquitous; relatively few individuals (cases or controls) had detectable levels in their gut (Table S5A ). This may be due to a lack of detection related to the depth of sequencing or because this genus is a marker of established disease in adults. However, overgrowth of the methane-producing Methanobrevibacter has recently been attributed to underlying constipation [27] . These slow-growing microbes thrive in environments with low water availability; methane further slows gut transit, promoting their self-survival [27] . Future studies should consider assessing gut transit to help disentangle whether these differences in Archaea are directly related to MS or are a consequence of comorbidity, such as constipation.
Bacteroides fragilis was also significantly depleted in our MS cases compared to controls, with findings consistent regardless of IMD exposure. Similar reductions are observed in early rheumatoid arthritis (n = 51) relative to fibromyalgia (n = 50), all prior to initiation of specific drug treatments [28] . Gut colonization of Bacteroides fragilis protects against experimental autoimmune encephalomyelitis (EAE) via polysaccharide A production and induction of interleukin-10 from CD4+ Foxp3+ regulatory T cells in the gut [26, 29] . Additionally, this species has been shown to ameliorate neurodevelopmental issues in a mouse model, indicating a gut microbiotaÀbrain connection [30] .
Exposure to an IMD influenced some findings but not all, suggestive of a partial but not full resolution of gut perturbation in addition to possible IMD-specific perturbations. Longitudinal studies are needed to establish the nature and direction of these associations. Putative functional differences congruent with the IMD known pharmacodynamics were observed, including predicted enrichment of microbial genes encoding immunomodulatory pathways [31] , involving CD8+, CD4+ and B-cell maturation and differentiation [31] . In addition, the MS gut microbiota was predicted as enriched for genes encoding glutathione metabolism [32] and lipopolysaccharide biosynthesis [33] . Whilst the latter appeared 'normalized' for the children exposed to an IMD, glutathione remained elevated regardless of IMD exposure status (all relative to controls). Glutathione is an important agent of the endogenous antioxidant defense system; loss of the oxidant/antioxidant balance has been implicated in MS neurodegeneration, and glutathione has been pursued as a therapeutic target and potential in vivo (brain) biomarker [34] . However, monitoring or targeting glutathione in the central nervous system is challenging. The potential for gut microbiota involvement in glutathione regulation -perhaps via metabotropic glutamate gut receptors -is intriguing and deserves further exploration [35] . Lipopolysaccharides can induce and worsen EAE [36] , perhaps via bystander activation, supporting an antigen-independent link between infection and autoimmunity [36] . A number of infectious disease related pathways upregulated in MS were also observed (Table S8) . A better understanding of these alterations is needed, especially if future ventures include interventions (e.g. diet or pre/probiotics) targeted at 'normalizing' the functional capacity of the gut microbiota in MS.
Others have explored the role of Fungi in MS, specifically Candida spp., via blood serum levels from 80 prevalent MS patients (local MS association members) relative to 240 age and sex matched blood donors [37] . The MS participants had a higher odds of serum antigen presence (versus absence) as measured by slot-blot analyses to Candida parapsilosis (OR = 7.3; 95% CI 3.2-16.6, P < 0.001) and Candida glabrata (OR = 3.0; 95% CI 1.5-6.1, P = 0.002) [37] . The authors indicated that findings were similar after excluding the MS participants (50%) exposed to an IMD or immunosuppressant or an extended MS disease duration (>10 years) [37] . Although the original sources of the Candida spp. were unknown (e.g. skin, nails, mouth, gut or vagina [38] ), it raises the possibility that other microbiota, such as Candida spp., could be associated with MS [37] .
The strengths of our study include a well phenotyped group of children sampled very close to MS onset and diagnosed using internationally recognized criteria by MS specialist pediatric neurologists. A well-validated microbiota pipeline was accessed [39] . In the absence of a validation cohort a secondary platform (DNA microarray) was accessed and an inferred functional metagenome assessment was included. Detailed demographic and lifestyle information indicated similarities between cases and controls; controls were also recruited from the same catchment area as cases. Pediatric MS represents a unique opportunity to explore the gut microbiota after relatively few years of life or disease have accrued. However, its relative rarity was reflected by our small numbers, and combined with the cross-sectional design precluded a rigorous assessment of potential confounders. Future studies need to carefully consider those identified here, including ethnicity, and ideally enroll IMD na€ ıve individuals. There was also considerable variation (from <10% to 100%) in the proportion of children with any given taxon in their gut. The contribution of low or high penetrance microbes which all differed significantly in abundance between cases and controls requires further investigation.
What triggers MS is unknown. Whether changes in the gut microbiota community play a role in precipitating or enabling the disease or in facilitating a persistent underlying immune dysregulation in MS is intriguing. It was found that even in the very early stages of MS, and independent of IMD exposure, taxon-level differences in the gut microbiota were observed. These perturbations suggesting a shift towards a pro-inflammatory state concur with observations in other autoimmune diseases, including traditionally 'gut unrelated' conditions such as rheumatoid arthritis [40] . Similarities between emerging MS studies were also observed; whether these indicate a 'gut signature' of MS or of broader autoimmune disease remains to be determined, as does the relationship with IMDs. A better understanding of the gut microbiota's role in MS may identify novel drug targets, preventative measures and pathways to improved health. honoraria or travel support from ACTRIMS, ECTRIMS and AAN. She has been an ad hoc consultant for Actelion, Roche and Novartis.
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